These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29305737)

  • 21. Current Treatment Options for Primary Biliary Cholangitis.
    Wong KA; Bahar R; Liu CH; Bowlus CL
    Clin Liver Dis; 2018 Aug; 22(3):481-500. PubMed ID: 30259848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Finding the cure for primary biliary cholangitis - Still waiting.
    Tanaka A; Gershwin ME
    Liver Int; 2017 Apr; 37(4):500-502. PubMed ID: 28371099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving prognosis in primary biliary cholangitis - Therapeutic options and strategy.
    Harms MH; van Buuren HR; van der Meer AJ
    Best Pract Res Clin Gastroenterol; 2018; 34-35():85-94. PubMed ID: 30343714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary biliary cholangitis: Old and novel therapy.
    Floreani A; Mangini C
    Eur J Intern Med; 2018 Jan; 47():1-5. PubMed ID: 28669591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigational drugs in phase II clinical trials for primary biliary cholangitis.
    Silveira MG; Lindor KD
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1115-1121. PubMed ID: 28836457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chenodeoxycholic acid: uses and limitations.
    Schoenfield LJ
    Hosp Pract; 1979 Oct; 14(10):57-65. PubMed ID: 478496
    [No Abstract]   [Full Text] [Related]  

  • 27. Obeticholic acid (Ocaliva) for primary biliary cholangitis.
    Med Lett Drugs Ther; 2017 Mar; 59(1517):53-55. PubMed ID: 28323811
    [No Abstract]   [Full Text] [Related]  

  • 28. Therapeutic advances for primary biliary cholangitis: the old and the new.
    Wang L; Zhang FC; Zhang X
    Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):615-21. PubMed ID: 26862931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary biliary cholangitis: a comprehensive overview.
    Lleo A; Marzorati S; Anaya JM; Gershwin ME
    Hepatol Int; 2017 Nov; 11(6):485-499. PubMed ID: 29164395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of primary biliary cholangitis prior to obeticholic acid availability.
    Durazzo M; Bonetto S; Fagoonee S; Morgando A; Pellicano R
    Minerva Med; 2018 Dec; 109(6):410-417. PubMed ID: 30022645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chronic cholestatic liver diseases : Differential diagnosis, pathogenesis and current treatment in adults].
    Hohenester S; Beuers U
    Internist (Berl); 2017 Aug; 58(8):805-825. PubMed ID: 28721532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Modern treatment of primary biliary cholangitis].
    Strassburg CP
    Internist (Berl); 2018 Jan; 59(1):105-112. PubMed ID: 29110023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacotherapy for primary biliary cholangitis: an assessment of medication candidacy and rates of treatment.
    MacDonald N; Loh R; Fenkel JM; Sass DA; Halegoua-DeMarzio D
    BMC Gastroenterol; 2024 Jan; 24(1):18. PubMed ID: 38178006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.
    Samur S; Klebanoff M; Banken R; Pratt DS; Chapman R; Ollendorf DA; Loos AM; Corey K; Hur C; Chhatwal J
    Hepatology; 2017 Mar; 65(3):920-928. PubMed ID: 27906472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From pathogenesis to novel therapies in the treatment of primary biliary cholangitis.
    Ronca V; Carbone M; Bernuzzi F; Malinverno F; Mousa HS; Gershwin ME; Invernizzi P
    Expert Rev Clin Immunol; 2017 Dec; 13(12):1121-1131. PubMed ID: 28994348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging drugs for the treatment of primary biliary cholangitis.
    Phaw NA; Dyson JK; Jones D
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):101-112. PubMed ID: 32253941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of cholestatic disease in 2017.
    de Vries E; Beuers U
    Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
    Yuan Z; Jia G; Han Y
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prevention of clogging of biliary stents by administration of levofloxacin and ursodeoxycholic acid].
    Sciumè C; Geraci G; Pisello F; Facella T; Li Volsi F; Modica G
    Chir Ital; 2004; 56(6):831-7. PubMed ID: 15771038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ursodeoxycholic acid: a second look. Primary biliary cirrhosis: dashed hopes.
    Prescrire Int; 2002 Jun; 11(59):67-9. PubMed ID: 12068838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.